Atalanta Therapeutics is focused on developing innovative therapies for neurological diseases through its proprietary RNA-based technology platform. The company leverages a unique approach to target and modulate gene expression, aiming to address the underlying causes of various neurodegenerative conditions. This platform enables the design of RNA molecules that can selectively silence or enhance specific genes, providing a versatile tool for therapeutic intervention. By utilizing this technology, Atalanta aims to create treatments that are not only effective but also have the potential for improved safety profiles compared to traditional small molecule drugs.

In addition to its RNA-based platform, Atalanta Therapeutics is committed to advancing its pipeline of product candidates that target specific neurological disorders. The company is focused on developing therapies that can penetrate the blood-brain barrier, a significant challenge in treating central nervous system diseases. Through its research and development efforts, Atalanta is working to bring forward novel solutions that can significantly improve the quality of life for patients suffering from debilitating neurological conditions. The integration of cutting-edge science and technology positions Atalanta Therapeutics as a leader in the field of RNA therapeutics for neurological applications.

United States

We are a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform. We were founded by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital. We are headquartered in Boston, Mass

Atalanta Therapeutics

Company Details